Corvus Pharmaceuticals (CRVS) Stock Price, News & Analysis

Company Overview

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.

Key Stats

• Today's Range: $3.71 to $4.00
• 50-Day Range: $3.21 to $4.50
• 52-Week Range: $1.75 to $10.00
• Volume: 970,972 shs
• Average Volume: 818,858 shs
• Market Capitalization: $272.68 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $15.00
• Consensus Rating: Buy

Corvus Pharmaceuticals Stock Analysis - MarketRank™

Corvus Pharmaceuticals scored higher than 51% of companies evaluated by MarketBeat, and ranked 571st out of 943 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Corvus Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Corvus Pharmaceuticals has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Corvus Pharmaceuticals are expected to grow in the coming year, from ($0.63) to ($0.49) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Corvus Pharmaceuticals is -4.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Corvus Pharmaceuticals is -4.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Corvus Pharmaceuticals has a P/B Ratio of 7.84. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

16.29% of the float of Corvus Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Corvus Pharmaceuticals has a short interest ratio ("days to cover") of 7.4.

Change versus previous month

Short interest in Corvus Pharmaceuticals has recently increased by 12.15%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Corvus Pharmaceuticals does not currently pay a dividend.

Dividend Growth

Corvus Pharmaceuticals does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

16.29% of the float of Corvus Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Corvus Pharmaceuticals has a short interest ratio ("days to cover") of 7.4.

Change versus previous month

Short interest in Corvus Pharmaceuticals has recently increased by 12.15%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 2.9 / 5
• News Sentiment: 1.30

News Sentiment

Corvus Pharmaceuticals has a news sentiment score of 1.30. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.90 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Corvus Pharmaceuticals this week, compared to 2 articles on an average week.

Search Interest

Only 2 people have searched for CRVS on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

MarketBeat Follows

1 people have added Corvus Pharmaceuticals to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Corvus Pharmaceuticals insiders have not sold or bought any company stock.

Percentage Held by Insiders

31.30% of the stock of Corvus Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

46.64% of the stock of Corvus Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

CRVS Stock Analysis - Frequently Asked Questions

How have CRVS shares performed this year?

Corvus Pharmaceuticals' stock was trading at $5.35 at the beginning of the year. Since then, CRVS stock has decreased by 25.2% and is now trading at $4.00.
View the best growth stocks for 2025 here.

How were Corvus Pharmaceuticals' earnings last quarter?

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) announced its quarterly earnings data on Thursday, May, 8th. The company reported ($0.13) EPS for the quarter, hitting the consensus estimate of ($0.13).
Read the conference call transcript.

When did Corvus Pharmaceuticals IPO?

Corvus Pharmaceuticals (CRVS) raised $75 million in an initial public offering (IPO) on Wednesday, March 23rd 2016. The company issued 4,700,000 shares at $15.00-$17.00 per share. Credit Suisse and Cowen and Company acted as the underwriters for the IPO and Guggenheim Securities, Cantor Fitzgerald and BTIG were co-managers.

How do I buy shares of Corvus Pharmaceuticals?

Shares of CRVS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Corvus Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Corvus Pharmaceuticals investors own include NVIDIA (NVDA), Viking Therapeutics (VKTX), Advanced Micro Devices (AMD), ADMA Biologics (ADMA), Rockwell Medical (RMTI), Axcelis Technologies (ACLS) and Protagonist Therapeutics (PTGX).

Company Calendar

• Last Earnings: 5/08/2025
• Today: 6/30/2025
• Next Earnings (Estimated): 8/05/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:CRVS
• CIK: 1626971
• Web: www.corvuspharma.com
• Phone: (650) 900-4520
• Fax: N/A
• Employees: 30
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $15.00
• High Stock Price Target: $21.00
• Low Stock Price Target: $11.00
• Potential Upside/Downside: +275.0%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 4 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($0.98)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$62.29 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -24.04%
• Return on Assets: -13.90%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 4.90
• Quick Ratio: 4.90

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.51 per share
• Price / Book: 7.84

Miscellaneous

• Outstanding Shares: 68,170,000
• Free Float: 46,832,000
• Market Cap: $272.68 million
• Optionable: Optionable
• Beta: 0.57